Eli Lilly and Company (LLY)vsOSR Holdings Inc (OSRH)
LLY
Eli Lilly and Company
$1,131.42
-2.41%
HEALTHCARE · Cap: $948.95B
OSRH
OSR Holdings Inc
$0.42
-1.12%
HEALTHCARE · Cap: $14.13M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 2748473% more annual revenue ($72.25B vs $2.63M). LLY leads profitability with a 35.0% profit margin vs 0.0%. OSRH trades at a lower P/E of 13.4x. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
OSRH
Avoid25
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Reasonable price relative to book value
Conservative balance sheet, low leverage
Attractively priced relative to earnings
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 32.4x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -14.7% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : OSRH
The strongest argument for OSRH centers on Price/Book, Debt/Equity, P/E Ratio.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book.
Bear Case : OSRH
The primary concerns for OSRH are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
LLY profiles as a growth stock while OSRH is a value play — different risk/reward profiles.
OSRH carries more volatility with a beta of 0.61 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 25/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →OSR Holdings Inc
HEALTHCARE · BIOTECHNOLOGY · USA
OSR Holdings Inc. is a prominent provider of integrated managed services, specializing in asset management and financial advisory solutions tailored for institutional clients. Leveraging cutting-edge technology and strategic collaborations, the company enhances operational efficiency while expanding its diverse service portfolio. Committed to sustainable growth and client-centric value creation, OSR Holdings distinguishes itself through innovation and exceptional service quality. With a proactive approach to emerging market opportunities, the firm upholds a robust risk management framework, ensuring long-term stability and success for its stakeholders.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?